Total Funding
50
31
Total FundingPost-IPO Debt raised
Growth Score
-1 pts
Heat Score
4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
185589
Oxurion is a biotech drug development company focused on developing therapies for retinal disorders, now focusing on diabetic eye diseases.
Tom Graney: CFA & Chief Financial Officer
Patrik De Haes: CEO
About the Company
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with retinal vascular disorders including diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide, as well as other
conditions, including wet age-related macular degeneration (AMD) and retinal vein occlusion (RVO).
